Navigation Links
ElutraSep Inc. Announces the Launch of the Cryptonite™ HV Filter Module for Cryptosporidium and Giardia Testing
Date:5/15/2009

ElutraSep, Inc. today announced the commercial launch of the Cryptonite™ HV Filter Module for Cryptosporidium and Giardia testing. www.elutrasep.com/app-Cryptosporidium.asp.

Atlanta, GA (PRWEB) May 15, 2009 -- ElutraSep, Inc. today announced the commercial launch of the Cryptonite™ HV Filter Module for Cryptosporidium and Giardia testing. www.elutrasep.com/app-Cryptosporidium.asp

Cryptonite™ HV is a hollow fiber filtration module designed to capture and concentrate Cryptosporidium and Giardia from non-filtered source and finished water samples. Cryptonite™ HV recently underwent method development for method 1623 at an internationally recognized EPA approved laboratory located in Saint Albans, Vermont.

Testing of the new Cryptonite™ HV filter exceeded the recovery requirements set forth for EPA method 1623 and will now allow laboratories an additional choice for sample concentration. Cryptonite™ offers advantages including a recovery procedure with a total elution volume of less than 50 milliliters, no specialized elution equipment or post filtration required and a start to finish process that can be completed in about two minutes.

"We were always aware of the potential benefits that our technology could bring to the EPA 1623 method but lacked a high volume design that could accommodate turbid source waters. Last year, we began the process of designing a high volume module that would be cost competitive and offer substantial advantages over the competition," said Jason Holt, president and CEO of ElutraSep. " Laboratories will no longer have to conduct tedious elution protocols or have to deal with hu
'/>"/>

Source: PRWeb
Copyright©2009 Vocus, Inc.
All rights reserved

1

GOOD

Page: 1 2

Related biology technology :

1. Dendreon Announces Publication of Phase 1 Study Highlighting Immunologic and Clinical Activity of Lapuleucel-T (Neuvenge(R)) in Advanced Breast Cancer Patients
2. YM BIOSCIENCES ANNOUNCES COMPLIANCE WITH AIM RULE 26
3. Emisphere Technologies, Inc. Announces Pricing of Registered Direct Offering
4. BioLife Solutions Announces Exclusive CryoStor(TM) Supply Agreement With the New England Cryogenic Center, Inc.
5. Carrington Announces Nasdaq Communication; Prepares for Shares to Be Quoted on the OTC Bulletin Board and Pink Sheets
6. China Kangtai Cactus Biotech Files 2nd Quarter 2007 10QSB and Announces Unaudited Quarterly Results
7. Cephalon Announces Positive Results from a Pivotal Study of FENTORA in Opioid-tolerant Patients with Non-cancer Breakthrough Pain
8. Advanced Life Sciences Announces Receipt of Nasdaq Staff Letter
9. ADVENTRX Announces Fast Track Designation Granted By the FDA For CoFactor For the Treatment of Metastatic Colorectal Cancer
10. Angiotech announces additional diameters of sutures to further expand its Quill(TM) SRS PDO product line
11. CNS Response Announces Fiscal Third Quarter 2007 Results
Post Your Comments:
*Name:
*Comment:
*Email: